Eloxx Pharmaceuticals, Inc. (ELOX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
+0.0001 (9,900.00%)
Oct 29, 2025, 4:00 PM EDT
Eloxx Pharmaceuticals Statistics
Important Dates
The last earnings date was Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ELOX has 3.30 million shares outstanding.
| Current Share Class | 3.30M |
| Shares Outstanding | 3.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +24.20% |
| Owned by Insiders (%) | 7.52% |
| Owned by Institutions (%) | 3.79% |
| Float | 3.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -73.24% |
| Return on Invested Capital (ROIC) | -124.75% |
| Return on Capital Employed (ROCE) | 110.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.14M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks. The beta is -163,568.64, so ELOX's price volatility has been lower than the market average.
| Beta (5Y) | -163,568.64 |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 54.28 |
| Average Volume (20 Days) | 4,392 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.29M |
| Pretax Income | -20.48M |
| Net Income | -20.48M |
| EBITDA | -19.24M |
| EBIT | -19.29M |
| Earnings Per Share (EPS) | -8.82 |
Balance Sheet
The company has 4.78 million in cash and 18.72 million in debt, giving a net cash position of -13.95 million or -4.23 per share.
| Cash & Cash Equivalents | 4.78M |
| Total Debt | 18.72M |
| Net Cash | -13.95M |
| Net Cash Per Share | -4.23 |
| Equity (Book Value) | -20.05M |
| Book Value Per Share | -6.53 |
| Working Capital | -17.84M |
Cash Flow
| Operating Cash Flow | -17.99M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.34% |
| Shareholder Yield | -7.34% |
| Earnings Yield | -6,206,666.67% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 2, 2022. It was a reverse split with a ratio of 0.025.
| Last Split Date | Dec 2, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |